Ascendis Pharma (ASND) stock

Medicines , market cap $17B

Medicines for endocrinology and oncology

Market cap $17B

$248.98

-0.91%

As of Monday's close · Live for Pro members at the open

Quality Score

Average

In its industry

#48of 291

Biotech

Checks firing

4of 14

Trending up

From 52-week high

-11.8%

Above the 200-day

ASND's Quality Score was unchanged on Mon, Nov 2, at 8.

Follow ASND's trial news. Pro members can get an alert when Ascendis Pharma files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ASND files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…Commission (EC) decision on Ascendis’ Marketing Authorisation Application (MAA) is expected during Q4 2026…”Filing with regulators · SEC filing · Oct 16

Why is ASND up?

Up 12% from Oct 16 to Oct 30 while the S&P 500 fell 1%.

Biotech stocks rose together, a median 7% from Oct 16 to Oct 30 (285 stocks); Ascendis Pharma rose 12% with them.

Sources: Price history, Oct 30, 2026

The timeline and its peers, for Pro members.

Key facts on ASND

Key facts on ASND
The chart	Above every average
Latest filing	20-F, Feb 11 Filed its annual report (20-F) for the year to Dec 31, 2025

1 more reason behind ASND's 8, free with an account →1 more reason behind ASND's 8, for Pro members.

ASND catalysts

Coming up

After its last 2 reports it closed +0.4% on average, higher 1 of 2 times.

1 more coming up and 8 past catalysts since 2023, with sizes and sources, for Pro members.Get in free →

What's next for ASND

Next step the company has named

Q4 2026“European Commission (EC) decision on Ascendis’ Marketing Authorisation Application (MAA) is expected during Q4 2026.”Filing with regulators · SEC filing · Oct 16

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway: Effects and Safety of Palopegteriparatide in Adolescents With Long-term HypoparathyroidismPhase 3 · Recruiting · 12 people · main data estimated Aug 2027 · NCT07706764

3 more trials, 133 filings, for Pro members.

Dilution on the horizon

Shelf registration (F-3ASR, filed Sep 18, 2024)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

SVP & Pao Mads Bodenhoff sold 3,000 shares on Sep 8. 7 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when ASND files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why ASND scores 8

Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

+4Chart checks 4 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.

No effect today: Run-up, Growth, Dilution, Volatility, Cash flow, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on ASND and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:36 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when ASND's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ASND and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

ASND has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ASND, and all 14 on every stock.Get in free →

ASND RSI today: 61.3, above its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1461.3
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 16 sessions ago.
50-day average$242.22
The price is 2.8% above it.
200-day average$238.27
The price is 4.5% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Feb 18, 2025.
ADX 1428.9
25 or more, with +DI above -DI.
Support$246.30
Swing low from Aug 28, 1.1% below the price.
Resistance$249.96
Swing high from May 22, 0.4% above the price.
52-week high$282.15
From Jul 9, 13.3% above the price.
52-week low$188.07
From Nov 13, 2025, 24.5% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $215.37 to $256.51.
Volume0.7x
Against its 20-day average, for the time of day.

The deep dive on ASND

What it does and how it makes money7 findings"In addition, we have the potential to receive sales-based milestone payments and tiered royalties on global net sales." (20-F for fiscal 2025)SEC filing · Feb 11, 2026"For SKYTROFA and the related TransCon technology, we own twenty-one patents in the United States and Europe that will expire between 2026 and 2040." (20-F for fiscal 2025)SEC filing · Feb 11, 2026
Where it stands1 findingFor Pro members1 finding on where ASND stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"We filed an opposition in September 2022, and on October 16, 2025, the European Patent Office ('EPO') Technical Boards of Appeal revoked the patent." (20-F for fiscal 2025)SEC filing · Feb 11, 2026A new heading in its "Risk Factors" this year: "If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs that we participate in, we could be subject to additional reimbursement requirements, penalties, sanctions and fines …" (20-F for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 11, 2026, against the one of Feb 12, 2025
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades ASND, for Pro members
Against its closest peers1 peerFor Pro membersASND against 1 peer, fact by fact, for Pro members

12 more findings on ASND, each with its source, for Pro membersGet in free →

How ASND ranks in Biotech

ASND is #48 of 291 by Quality Score.

How ASND ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	ARQTArcutis Biotherapeutics		Open for its score
	ARTVArtiva Biotherapeutics		Open for its score
	ATTOAttovia Therapeutics		Open for its score
	AUPHAurinia Pharmaceuticals		Open for its score
48	ASNDAscendis Pharma	4/14	8

When does ASND report earnings, and what happens after?

Expected to report Wed Nov 18, before the open (in 16 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

+4.3%-3.6%

May 7Aug 13

Reported	When	Gap	Reaction	5 sessions
Aug 13, 2026Before open	Before open	-2.0%	-3.6%	+1.6%
May 7, 2026Before open	Before open	-5.3%	+4.3%	+3.3%

ASND closed higher after 1 of its last 2 reports.

2 quarters of ASND’s results read from its 6-K filings, the newest filed Aug 13, 2026: its sales and profit, quarter by quarter, for Pro members.Get in free →

ASND sales and profit by year

Sales and profit by year

Sales grew in six of the last seven years, to €720M in 2025. It lost money in each of the eight years.

ASND share count over time

Shares of ASND outstanding, as filed
Shares outstanding	As of
62M	Dec 31, 2025
60.7M	Dec 31, 2024
57.7M	Dec 31, 2023
57.2M	Dec 31, 2022

Offerings, shelves, and splits of ASND, from its filings
From its filings	Filed
Raised $300M in a sale of shares, about 2% of its market value	Sep 20, 2024
Registered shares for a later sale (F-3ASR)	Sep 18, 2024

Insiders trading ASND

ASND insider trades

2 insiders bought $777K across 9 filings, and 3 insiders sold $5.5M across 3 filings, in the last 6 months. The newest:

SellMads Bodenhoff$811KSVP & PAOat $270.19 on Sep 8, filed Sep 9

SellMads BodenhoffSVP & PAO$811Kat $270.19 on Sep 8, filed Sep 9

All 12 insider filings on ASND from the last six months, for Pro members.Get in free →

All ASND insider trades

ASND's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Scott Thomas SmithEVP & Chief Financial Officer · 1 trade
Scott Thomas SmithEVP & Chief Financial Officer · 1 trade
Flemming Steen JensenOfficer · 1 trade
Mads BodenhoffSVP & PAO · 1 trade
Jean Jacques BienaimeDirector · 7 trades
Lars HoltugDirector · 1 trade

See insider trades by person

About Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

1,189 employeesascendispharma.com

What Ascendis Pharma says it competes with

“The pharmaceutical industry is very competitive and subject to rapid and significant innovation.”

From its annual report, SEC filing · Feb 11, 2026

2 more sentences, what it says it does, and its sales by region, for Pro membersGet in free →

ASND's score card

Ascendis Pharma (ASND): Quality Score 8, Average, #48 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would move ASND's score: 5 things
6 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayAug 18Jean Jacques Bienaime bought ASND$270K at $245.85, filed Aug 18

Alerts are optional.

See ASND's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: ASND's Quality Score is 8 (Average), #48 of 291 in Biotech. Insiders bought $777K and sold $5.5M in the last 6 months (Form 4).

Is ASND a good stock to buy? What its Quality Score says

ASND scores 8 today, which Breakaway calls Average. It is #48 of 291 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 12% from Oct 16 to Oct 30 while the S&P 500 fell 1%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ASND's Quality Score?

ASND scores 8 today, which Breakaway calls Average (6 to 10). That is #48 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ASND's 8.

Are insiders buying ASND?

2 insiders bought $777K across 9 filings, and 3 insiders sold $5.5M across 3 filings, in the last 6 months. The newest is Mads Bodenhoff, SVP & PAO, who sold $811K on Sep 8. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.